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Patients undergoing infrainguinal bypass to treat
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underprescribed cardioprotective medications:
Effect on graft patency, limb salvage, and
mortality
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Mukherjee, MD, Sanjay Rajagopalin, MD, Gilbert R. Upchurch, Jr, MD, James C. Stanley, MD, and
Kim A. Eagle, MD, Ann Arbor, Mich
Introduction: Established American Heart Association guidelines recommend the use of statin drugs, angiotensin
converting enzyme (ACE) inhibitors, and antiplatelet agents in patients with systemic atherosclerosis, such as those
undergoing operative intervention to treat peripheral atherosclerotic disease. Many of these patients have not received
treatment of coronary heart disease and have not been prescribed these medications. Whether statin drugs and ACE
inhibitors confer an improvement in graft patency, limb salvage, and operative mortality is unknown.
Methods: Consecutive patients who underwent infrainguinal bypass between 1997 and 2002 were evaluated for
demographic data, comorbid disease, medication use, as well as cumulative graft patency, limb salvage, and mortality.
Univariate, multivariate logistical regression, and Kaplan-Meier analyses were performed. P < .05 was considered
significant.
Results: Two hundred ninety-three patients (mean age, 64 years; 67% men) underwent 338 infrainguinal bypass
procedures with autologous vein (n  218), prosthetic grafts (n  88), or composite prosthetic-vein grafts (n  32).
Limb salvage was the operative indication in 75% of procedures. Coexisting diseases included hypertension (70%),
diabetes (52%), hyperlipidemia (37%), coronary heart disease (51%), congestive heart failure (14%), and active tobacco use
(30%). Statin drugs were taken by 56% of patients, ACE inhibitors by 54% of patients, and antiplatelet agents or warfarin
sodium (Coumadin) by 93% of patients. Postoperative graft surveillance was done in 39% of patients. Cumulative graft
patency was 73%, limb salvage was 85%, and mortality was 9%, with a mean follow-up of 17 months.
Factors independently associated with increased graft patency included statin drug use (odds ratio [OR], 3.7; 95%
confidence interval [CI], 2.1-6.4), male sex (OR, 2.8; 95% CI, 1.6-5.0), and graft surveillance (OR, 2.4; 95% CI,
1.3-4.5). Factors associated with decreased amputation rate were statin drug use (OR, 0.34; 95% CI, 6.15-0.77) and graft
surveillance (OR, 0.23; 95% CI, 6.1-0.63). Factors associated with decreased mortality included graft surveillance (OR,
0.18; 95% CI, 0.1-0.56), whereas congestive heart failure (OR, 6.5; 95% CI, 2.5-17) and hemodialysis-dependent renal
failure (OR, 29; 95% CI, 6.1-140) were associated with increased mortality. Kaplan-Meier analysis showed that only ACE
inhibitors were associated with lower mortality (P  .05)
Conclusions: Patients undergoing infrainguinal bypass are undertreated with respect to cardioprotective medications.
ACE inhibitor use is associated with lower mortality, and statin drug use is associated with improved graft patency and
limb salvage. Institution of consensus guidelines concerning these medications should be considered by all vascular
specialists, including vascular surgeons. (J Vasc Surg 2004;39:357-65.)
Systemic atherosclerosis is a protean disease, with cor-
onary heart disease (CHD) and stroke accounting for most
deaths in the United States. Level I medical evidence
suggests that certain medications are beneficial for all pa-
tients with systemic atherosclerosis, and include angioten-
sin converting enzyme (ACE) inhibitors, 3-hydroxy-3-
methylglutaryl coenzyme A (HMG co-A) reductase
inhibitors (statin drugs), and antiplatelet agents.1-7 Indeed,
the reductions in morbidity and mortality from cardiovas-
cular-related disease accompanying the use of ACE inhibi-
tors and statin drugs may in part be independent from their
antihypertensive and lipid-lowering effects, respectively. A
significant number of patients with systemic atherosclerosis
have peripheral arterial disease (PAD), ranging from clau-
dication to rest pain or tissue loss. Many of the latter
patients, who may or may not be under the care of a
cardiovascular medicine specialist, may not be receiving
these cardioprotective medications.8-12 In addition, be-
cause compliance with some of these medications is poor,13
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this patient population may be underprescribed drug therapies
that can reduce cardiovascular morbidity and mortality.
As vascular surgeons expand their training to include
endovascular techniques, it is just as important that they
afford their patients optimal medical therapy for atheroscle-
rotic disease. Indeed, these therapies may have a greater
long-term salutatory effect than any given operative inter-
vention. Both statin drugs and ACE inhibitors have bene-
ficial effects with regard to arterial vessel wall remodeling in
the setting of advanced atherosclerosis.14-17 Although
-blockers are effective antihypertensive agents with
proven benefit in patients undergoing major vascular oper-
ations, no studies have shown an independent protective
effect for all patients with systemic atherosclerosis.7,18
Taken together, the hypothesis that these medications are
beneficial in promoting graft patency and decreasing limb
loss in patients with PAD is logical. This subject receives
support from clinical studies in patients undergoing coro-
nary artery bypass grafting.17,19,20 Antiplatelet agents have
long been known to be benefit overall patient mortality, as
well as improving graft patency, and are accepted as the
standard of care.3,6,7,21,22
This study examines the use of proved cardioprotective
medications on graft patency, limb loss, and death in a
group of patients with clinically severe manifestations of
PAD undergoing infrainguinal surgical revascularization.
METHODS
All patients undergoing an infrainguinal bypass at the
University of Michigan Health System from 1997 to 2002
comprised the study population. This period was chosen
because data regarding the beneficial effects of both ACE
inhibitors and statin drugs had recently been pub-
lished.1,2,5,7 Patient demographic data, and common car-
diovascular risk factors such as hypertension, diabetes, hy-
perlipidemia (total cholesterol220 mg/dL, based on the
hospital’s pathology laboratory range), CHD, chronic
obstructive pulmonary disease, obesity, stroke, history of
coronary artery bypass grafting, history of percutaneous
transluminal coronary angioplasty (PTCA), and hemodial-
ysis-dependent renal failure (HD-RF) were noted. Total
cholesterol and low-density lipoprotein—calculated
(LDL-C) were abstracted from the period around the time
of the index procedure. Medication use was documented,
either during the preoperative, perioperative, or postoper-
ative period, to include ACE inhibitors, aspirin, -blockers,
clopidigrel, warfarin sodium (Coumadin), multivitamin,
and statin drugs. For purposes of analysis, medications were
considered positive if the patient had been taking that
medication at any time, and negative if there was no docu-
mentation of such in the chart.
Operative indications for the infrainguinal bypass pro-
cedure were defined as claudication, rest pain, tissue loss, or
both rest pain and tissue loss.23 Conduits included autolo-
gous saphenous or other vein, prosthetic grafts (Dacron or
polytetrafluoroethylene), or composite prosthetic-vein
grafts. For purposes of comparison, autologous vein grafts
were compared with prosthetic grafts, which included com-
posite prosthetic-vein grafts. Tobacco use was defined as
current use at the most recent follow-up.
Mortality and amputation rates over the course of
follow-up were determined. Patients who died periopera-
tively (n 4) and those with no discernible follow-up (n
10) were not included in the analysis. Bypass graft patency
was assessed as cumulative patency. It was not the purpose
of this study to compare levels of patency (eg, primary vs
secondary). Graft occlusion was defined by either a nota-
tion in the chart, a significant decrease to baseline in ankle
brachial index (ABI), or documented at duplex ultrasonic
graft interrogation. Repeat bypass procedures were defined
as new bypass procedures, whereas patch angioplasty or
percutaneous angioplasty procedures were documented as
being performed because of failing grafts.
Statistical analysis. Descriptive statistics were used,
and univariate analyses were performed with the 2 test for
categorical variables and the Student t test for continuous
variables. Defined outcome measures of cumulative graft
patency, amputation, and death were analyzed with univar-
iate analysis. Significant factors were then entered into a
multivariate logistic regression model to determine the
independent association of demographics, risk factors,
medications, and operative variables to these defined out-
comes. The findings were presented as odds ratio (OR)
with 95% confidence interval (CI). Cox proportionate haz-
ards modeling was used to compare the medication effect
over time on graft patency and mortality. Kaplan-Meier life
table analysis was done to estimate overall survival and
medication use on survival, consistent with recommended
reporting standards.23 A software statistical program was
used for all computations (SAS Institute, Cary, NC). P 
.05 was considered significant. This study was approved by
the University of Michigan Institutional Review Board.
RESULTS
The patient group comprised 293 patients who under-
went 338 infrainguinal bypass procedures, with a mean age
of 64 years and with 67% men and 33% women. This
Fig 1. Cardiovascular medication use in a population of patients
undergoing infrainguinal bypass procedures over 5 years. AP,
Antiplatelet therapy; AC, anticoagulant therapy; BB, -blocker
use; ACEI, angiotensin converting enzyme inhibitor use; MV,
multivitamin.
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patient cohort had risk factors similar to those in most
patients with operative PAD (Table I). Of note, hyperten-
sion and diabetes mellitus were most common, and current
tobacco use was documented in 30% of patients after the
operative intervention.
Indications for infrainguinal arterial bypass were clau-
dication in 26% (n  88), rest pain in 27% (n  90), rest
pain and tissue loss in 31% (n  104), and popliteal
aneurysm in 4% (n  14). Surgical bypass procedures
consisted of femoral to popliteal artery in 53% (n  178),
femoral to distal arteries (anterior tibial, peroneal, or pos-
terior tibial) in 43% (n  145), and combined inflow and
femoral to popliteal or distal bypass in 1.4% (n  5). The
bypass conduit most commonly used was autologous vein,
with saphenous vein in 61% (n 206) and upper extremity
vein in 5% (n  12). Prosthetic conduit was used less
commonly, in 26% (n 88), and composite prosthetic-vein
grafts were used in 9.5% (n 32). A secondary intervention
was undertaken in 51 patients with failing bypass grafts,
with either percutaneous method (endovascular angio-
plasty, n  34) or open technique (patch angioplasty, n 
17). Repeat infrainguinal bypass procedures were done
because of previous failed bypass grafts in 85 patients.
Postoperative duplex graft surveillance was performed in
39% of patients one or more times. Intraoperative methods
of evaluating immediate bypass graft patency, such as arte-
riography or duplex scanning, were not assessed in this
study.
Cumulative bypass graft patency was 73%, with mean
follow-up of 17.5  14 months. Note that 103 patients
were followed up for more than 24 months, whereas 85
patients were followed up for less than 6 months. The mean
preoperative ABI in the affected limb was 0.42  0.27,
compared with a mean postoperative value of 0.75  0.27
(P .05). Amputation was performed in 45 patients (13%)
over the course of follow-up, and the overall mortality
during follow-up was 8% (n  26). Most deaths were
related to sequelae of chronic renal failure (n  6), malig-
nancy (n  5), cardiovascular disease, or multiple organ
failure (n  8).
Most patients were receiving antiplatelet therapy or
anticoagulant agents, including aspirin in 76%, clopedigrel
in 27%, and sodium warfarin in 30% (Fig 1). Similarly, most
patients (n  202, 69%) were receiving a -blocker. ACE
inhibitors and statin drugs were used in approximately half
of the patients. Multivitamins were used by a minority of
patients. Medication intolerance was 2% for all agents ana-
lyzed, including aspirin intolerance in 5 patients and ACE
inhibitor intolerance in 3 patients. Of interest, no -blocker
intolerance was documented in this patient group, includ-
ing 71 patients with chronic obstructive pulmonary disease.
Total cholesterol and LDL-C cholesterol levels were com-
pared between patients receiving or not receiving statin
drugs, and no significant difference was found. In the statin
group, total cholesterol was 183 51 mg/dL, vs 184 51
mg/dL in the non-statin group (P  .86), and LDL-C in
the statin group was 94 34 mg/dL;, vs 99 32 mg/dL
in the non-statin group (P .36).
Univariate analysis of demographic data, comorbidi-
ties, and medications revealed varying associations with the
primary outcome end points. Aspirin or warfarin sodium,
ACE inhibitors, statin drugs, and -blocker use correlated
with improved graft patency and decreased amputation
rates. In general, female gender, more severe ischemic
symptoms at presentation, prosthetic graft use, and repeat
bypass procedures or need for secondary interventions to
revise failing grafts conferred an increased risk for graft
failure and amputation. In contrast, increased mortality was
related to severity of ischemia at presentation and underly-
ing medical conditions, such as congestive heart failure
(CHF) and HD-RF.
Multivariate analysis revealed bypass graft patency to be
significantly worse when the bypass was constructed with a
prosthetic graft or a secondary intervention was required
(Table II, A). A twofold to threefold improvement in
Table I. Comorbid conditions in study patients
Comorbidities n %
Hypertension 205 70
Diabetes mellitus 155 53
Hyperlipidemia 142 48
Coronary heart disease 150 51
Congestive heart failure 41 14
Chronic obstructive pulmonary disease 62 21
Obesity 12 4
Stroke history 38 13
Percutaneous coronary intervention 29 10
Coronary artery bypass graft 53 18
Hemodialysis-dependent renal failure 14 5
Current tobacco use 88 30
Table II. Multivariate analysis against graft patency,
amputation, and mortality
OR 95% CI P
A. Graft patency
Prosthetic graft 0.428 0.25-0.75 .003
Need for revision 0.33 0.16-0.67 .002
Graft scan 2.4 1.3-4.5 .006
Male gender 2.8 1.6-5.0 .001
Statin drug 3.7 2.1-6.4 .001
B. Amputation
Graft scan 0.23 0.1-0.63 .007
Statin drug 0.34 0.15-0.77 .01
Repeat bypass 2.7 1.2-6.5 .02
Prosthetic graft 2.7 1.2-6.4 .02
Multivitamin 3.1 1.2-7.6 .02
C. Mortality
Graft scan 0.18 0.1-0.56 .003
PTCA 3.5 1.1-11 .03
CHF 6.5 2.5-17 .001
HD-RF 29 6.1-140 .001
PTCA, Percutaneous transluminal coronary angioplasty; CHF, congestive
heart failure; HD-RF, hemodialysis-dependent renal failure; OR, odds ratio;
CI, confidence interval.
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bypass patency was associated with postoperative graft sur-
veillance, male gender, and use of statin drugs. Of interest,
the indication for operation, anatomic type of bypass, and
comorbidities had no independent effect on graft patency.
Amputation risk was nearly 80% less in those patients
undergoing graft surveillance and statin therapy (Table II,
B). In contrast, use of a prosthetic conduit, repeat bypass
procedures, and multivitamin use were associated with
nearly threefold increase in amputation. Mortality was sig-
nificantly less in those patients undergoing graft surveil-
lance, whereas patients who had undergone PTCA or had
CHF or HD-RF had markedly increased mortality rates
(Table II, C).
Analysis solely for medication effect over time with Cox
proportionate hazards modeling demonstrated that only
therapy with statin drugs (hazard ratio [HR], .52; 95% CI,
.33-.82; P .005) or aspirin (HR, .52; 95% CI, .32-.83; P
 .007) was associated with significantly decreased risk for
graft occlusion. Only aspirin therapy was associated with
lower mortality (HR, .43; 95% CI, .19-.98; P  .05). No
other medications were independently associated with im-
proved outcomes.
Kaplan-Meier life table analysis showed overall mean
survival of 53 months in the entire population (Fig 2).
Analysis of medication effect documented that ACE inhib-
itor use was associated with improved survival, and aspirin
therapy showed a positive trend (P  .067; Figs 3, 4).
Statin drugs, -blockers, and other anticoagulant agents
were not significantly associated with survival.
DISCUSSION
Patients with manifestations of PAD requiring surgical
intervention represent an ideal group of patients to receive
cardioprotective medications.9,24,25 Indeed, claudication
and, by definition, rest pain or tissue loss are recognized as
a class I CHD equivalent that should prompt medical
therapy, and behavioral and risk factor modification, in-
cluding tobacco cessation and a structured exercise pro-
gram.2,7 The present study confirms what others have
shown in a similar patient population; that is, these patients
are significantly undertreated with cardioprotective medi-
cations.12 Patients not receiving these medications in the
current study had inferior infrainguinal graft patency and
limb salvage rates, and increased mortality. Antiplatelet and
anticoagulant therapies were highly prevalent in this study,
suggesting that these classes of medications are more uni-
formly prescribed by vascular surgeons. This report and
others26,27 suggest that graft patency is better in men than
in women, yet the overall effect of cardioprotective medi-
cations in patients with PAD is not thought to be gender-
specific.
A striking statistic is that most patients with PAD who
require an intervention will not die as a result of the
operation, but from a cardiac cause. A 5-year longitudinal
Fig 2. Kaplan-Meier plot depicts overall survival over time. Dashed lines, 95% confidence intervals surrounding the
main plot.
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Fig 3. Kaplan-Meier plot compares survival in patients who were taking angiotensin converting enzyme inhibitors with
those who were not taking this medication. The difference was significant by log-rank test, at P  .05. Dashed line,
Portion of plot where standard error is greater than 10%.
Fig 4. Kaplan-Meier plot compares survival in patients who were taking aspirin with those who were not taking this
medication. A trend was observed, but the difference did not reach significance (P  .067, log rank test). Dashed line,
Portion of plot where standard error is greater than 10%.
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study of 1200 Veterans Affairs hospital patients with clau-
dication demonstrated an annual mortality rate of 12%. The
mortality rate was higher in patients with diminished ABI,
older age, diabetes, and history of stroke, with most deaths
in this cohort related to CHD.28 A study of nearly 4300
male veterans who underwent peripheral arterial bypass
procedures using the VA National Surgical Quality Im-
provement Program database showed 30-day mortality was
low, at 2%, but over the next 44 months almost 50% of
these patients died.29 Similarly, low ABI correlates directly
with mortality over 10 years, with nearly sixfold increase in
deaths from cardiovascular diseases.30 Taken together,
these data support the notion that procedural morbidity
and mortality are low, but that long-term consequences of
systemic atherosclerosis account for most deaths, and effec-
tive therapies appear to be underused.
Data in this report support the tenet that the protective
effect that statin drugs confer on graft patency and limb
salvage is greater than the effect of conduit type, severity of
ischemia, or vascular comorbidities. Previous reports have
confirmed a number of well-recognized prognostic factors
in lower extremity bypass outcomes, but few to date have
analyzed the role of cardiovascular medications used, out-
side of antiplatelet or anticoagulant use.31,32 An exception
was one report of infrainguinal arterial bypass that found
only a trend with respect to benefit of statin drugs and ACE
inhibitors, whereas calcium channel blockers were associ-
ated with improved graft patency.33 However, that study
had fewer patients than the current study, and excluded
patients from analysis who did not survive beyond 12
months. Furthermore, unlike the statin drugs and ACE
inhibitors, there is no level I evidence that calcium channel
blockers confer lower cardiovascular mortality or decrease
the need for coronary revascularization.2,7,25
Statin drugs not only have long-term benefit, but also
periprocedural benefit. For example, discontinuation of a
statin drug around the time of an acute coronary syndrome
or a percutaneous intervention increases mortality.34,35 In
addition, a recent report suggests that perioperative statin
use decreased mortality in patients undergoing major vas-
cular procedures.36 Though not mechanistically discernible
from this report, that total cholesterol and LDL-C concen-
trations were similar between patients receiving and not
receiving statin drugs suggests an effect of these agents
independent of their lipid-lowering activity. The basic cel-
lular protective mechanism of statin drugs is just starting to
be delineated, but stabilization of atherosclerotic plaque
remodeling through matrix metalloproteinases and leuko-
cytic-matrix interactions has been demonstrated in studies
in both animals and human beings.14,15,37
ACE inhibitors confer the benefit of lower mortality in
patients with systemic atherosclerosis,5 and was suggested
by Kaplan-Meier analysis in the current study. These med-
ications are particularly beneficial in patients with CHF,
which is probably related to vascular wall remodeling. It
was not surprising that ACE inhibitors were not associated
with increased graft patency or limb salvage, inasmuch as
no precedents for this effect exist in the literature. How-
ever, ACE inhibitors are associated with a decreased need
for coronary revascularization in patients at risk,5 though
not necessarily because of lower PTCA rates.38 Thus the
mechanism of ACE inhibitors on atherosclerosis is com-
plex, and probably not directly related to reduced athero-
sclerotic burden. Of interest, multivitamins do not appear
to be of any benefit. Why this might be the case is not clear.
This study did not analyze the specific types of multivitamin
used, and while vitamin B6, vitamin B12, and folate decrease
hyperhomocysteinemia, which is proatherogenic,7,25 vita-
min E has no beneficial effects and may actually worsen
clinical outcomes in patients with atherosclerosis. For ex-
ample, antioxidants have a strong trend toward increasing
the risk for coronary revascularization procedures, as com-
pared with placebo controls.1
The -blocker class of antihypertensive agents used in
the current study did not confer an independent protective
effect on mortality, graft patency, or amputation. It is likely
that patient numbers were too small and follow-up too
brief to reveal a significant effect in the current study.
Furthermore, whether patients receiving -blockers
achieved a resting heart rate less than 70 bpm could not be
ascertained. Nevertheless, to give patients with vascular
disease -blockers preoperatively is supported by level I
evidence,18 and that most patients in this study were taking
these agents represents an appropriate practice pattern for
vascular surgeons. However, this is not the case with regard
to use of statin drugs and ACE inhibitors, which suggests
potential practice implementation gaps in the authors’
practice.8,11
The very strong protective effect of graft surveillance on
patency and limb salvage was not surprising, but its inde-
pendent positive effect on mortality was unexpected. Other
reports have confirmed the usefulness of graft surveillance,
but mortality as an outcome has not been routinely evalu-
ated.39,40 While it may be that patients who maintain a
patent graft and limb salvage may live longer, it is also
possible that regular graft surveillance is a surrogate marker
for better patient compliance with medications and lifestyle
modifications. Of no surprise, HD-RF and CHF were
strongly associated with mortality. Both of these diseases
confer a poor long-term survival risk, which suggests that
thoughtful judgment be exercised when offering surgical
bypass to these patients. While HD-RF was not associated
with significantly worse graft patency in this and earlier
studies,32 others have found that the cost per life-year saved
is high and that primary amputation in selected patients
should be considered.41
The limitations of this study include its retrospective
nature; the large confidence intervals of certain indepen-
dent variables, attributable to small patient numbers; the
benefits of medication use in the preoperative versus post-
operative periods could not be differentiated; and titration
of statin agents to a specific therapeutic efficacy was not
defined. Analysis of prospectively acquired data should
better define the benefits of these medications in this group
of patients with severe atherosclerosis. Further studies
would best be undertaken in a multifactorial prospective
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manner. For example, simple, standard multiple-modality
therapy for diabetes mellitus resulted in significant im-
provement in cardiovascular morbidity and mortality,42
and intensive antihypertensive management with currently
available medications in a group of patients with PAD was
associated with lower mortality.43
Data from this study support certain clinical recom-
mendations. All patients with symptomatic claudication or
more severe symptoms should be considered for antiplate-
let therapy, ACE inhibitors, and statin drugs. The benefits
of establishing good vascular medical care are slow to
accrue, but the appropriate use of these cardioprotective
medications is likely to significantly prolong patient life
and, as suggested in this study, enhance the durability of
surgical bypass procedures for PAD.
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DISCUSSION
Dr Michael S. Conte (Boston, Mass). Peter, that’s a great
paper, and I congratulate you on addressing this important topic.
I want to focus on the issue of statins. We’ve also recently
submitted some data to our regional vascular society, with remark-
ably similar results in terms of graft patency, with a relative risk
reduction that’s very similar to yours. So I do think there’s some-
thing there. But there are a couple of questions I want to ask.
First, you alluded to the fact that statin therapy is supported by
level I evidence for everyone with peripheral atherosclerosis. I am
not sure that is necessarily the case. Certainly patients without
dyslipidemias remain an open question. As you know, the effects of
statins are not only related to cholesterol loweringm but are also
related to reduction in systemic inflammation markers. So the
question of how they might be acting here is critical. Did you
actually look at cholesterol levels in these patients to try to deter-
mine if the influence of statins was related to patients who had
cholesterol-lowering effects or not?
The second question is whether or not we’re really looking at
associations of different treatment groups in your study; that is, are
we really just looking at improved outcomes for a group of patients
who got autogenous vein grafts, got duplex scanning, and also got
their cardiac medications, versus patients who got prosthetic grafts
and less aggressive treatment overall?
Dr Peter K Henke. I agree, we did make that statement a
little bit strongly. And I conferred with my vascular medicine
colleagues who are the coauthors, and they are taking a little bit of
leap of faith with regard to if you have symptomatic claudication
that does count toward a coronary heart disease equivalent.
They’re more and more aggressively treating patients with statins,
regardless of their lipid levels. Now, I must admit that with the
consensus statement, it’s not quite that bold.
The multivariate logistic regression should have made the
independent variables stand out as independent. But yes, I agree,
those patients certainly who had a vein graft and particularly
underwent graft scanning did do better. But, again, I can’t say if
that group of patients had every one of those same factors.
We did not have recent cholesterol levels on all patients, and
this was not analyzed in this study.
Dr Bruce M. Elliott (Charleston, SC). I’d really like to
congratulate your group on a superb series here. We always learn a
great deal from the Michigan group.
I question the use of the -blockade in your series. It’s pretty
commonly accepted as level evidence, the use of prophylactic
-blockade, in patients undergoing peripheral vascular reconstruc-
tion. Our own group, in a smaller series, actually found that the
routine use of prophylactic -blockade had an adverse effect on our
30-day mortality. And I notice in your series that both by univar-
iate and multivariate analysis there was no impact on survival with
-blockade, and I’d like your comments on that.
Dr Henke. Thank you for those comments and compliment.
We routinely, again based on a study by Poldermans et al and
their prospective study looking at -blockade in patients with very
high-risk coronary disease undergoing vascular surgery, conferred
a significant risk reduction and death. So we have adopted that
policy, and we continue to use that without noted excessive
mortality.
I have not seen any noted increase in terms of poor outcome
with -blockade. It certainly didn’t stand out as strongly as the
statins did in terms of graft patency or amputation. But I think I’ve
observed just anecdotally that in our patient population the num-
ber of MIs that we have postoperatively is lower, and in those
patients who have myocardial infarction, it seems to be less severe
than in those patients who are not on beta-blockade.
Dr Mark R. Nehler (Denver, Colo). There are several series
in Europe looking at C-reactive protein as a marker for patients
who aren’t going to get limb salvage despite technical successful
revascularization or are going to die in the early 6- to 12-month
period. Similar data exist in the cardiac literature.
We have a large critical limb ischemia database, and I’ve been
impressed that 40% of several thousand blood pressure readings
show systolic hypertension, blood pressures greater than 140. It
appears that we’re poorly able to control patients’ blood pressure.
Dr Henke. It would be very nice to have C-reactive protein
levels. Because this was retrospective and a high-sensitivity CRP
was not routinely available, that information was not available.
I agree, certainly some of the most simple things with regards
to controlling these risk factors are the hardest things to change in
our patients. And I totally agree with you, in every clinic that I
have, systolic hypertension is very prevalent.
Dr Eric Wahlberg (Stockholm, Sweden). I also enjoyed your
presentation. I was a little bit confused, though, about your final
remark. As you mentioned, there is ample evidence for patients
with peripheral arterial disease to use these medications you are
discussing, if nothing else, as secondary prophylaxis for coronary
disease. Still you propose a randomized trial?
Dr Henke. Well, I don’t think we should do it with each
individual agent, because I think that would be probably not
ethical, knowing what you just said and what we know. But I think
to better nail down in this patient population, there have been a
couple of recent articles where investigators looked at very high-
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intensity common medications and risk factor modifications, and
compared it to routine care, and showed a much better outcome in
terms of overall mortality. So I think it’s something that just takes
a lot of kind of leg work to get done, not real glamorous.
Dr John W. Hallett (Bangor, Me). Given that many of these
medications are expensive, and those of us who are in rural areas
where a third of the people have no health care, I’ve noticed that
some of these patients would like to be on these drugs or they have
been prescribed but they cannot afford them. Do you have any way
in your database to look at the socioeconomic level or the payer
means for these patients, to see whether that really is the reason
that many of them are undertreated?
Dr Henke. That’s a great question and obviously brings out
the whole issue of prescription benefit cost.
I do not have this in this database. I work a lot at the Veterans
Hospital, so they get a lower copay. And again, I’ve noticed that
there is a large influx of veterans who had been in the private sector
who are now coming over to the Veterans Hospital because of the
prescription benefit plan. We hope that will improve their compli-
ance. But I agree, cost is a big issue.
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